Litigation Details for Galderma Laboratories LP v. SEEGPharm SA (N.D. Tex. 2016)

Galderma Laboratories LP v. SEEGPharm SA (N.D. Tex. 2016)

Docket		Date Filed	2016-08-29
Court	District Court, N.D. Texas	Date Terminated	2017-01-10
Cause	35:271 Patent Infringement	Assigned To	David C. Godbey
Jury Demand	Plaintiff	Referred To
Patents	6,881,726; 7,348,317
Link to Docket	External link to docket

Details for Galderma Laboratories LP v. SEEGPharm SA (N.D. Tex. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-08-29				External link to document
2016-08-29	1		Attachments: # 1 Exhibit(s) A - Patent No. 6,881,726, # 2 Exhibit(s) B - Patent No. 7,348,317, # 3 Cover Sheet…2017 3:16-cv-02497 830 Property Rights: Patent Plaintiff District Court, N.D. Texas	External link to document

Galderma Laboratories LP v. SEEGPharm SA Litigation Analysis

Last updated: February 19, 2026

Galderma Laboratories LP (Galderma) litigation against SEEGPharm SA (SEEGPharm) concerning an alleged patent infringement for a topical acne treatment, adapalene and benzoyl peroxide gel, reached a settlement. The case, filed in the U.S. District Court for the District of New Jersey (3:16-cv-02497), involved allegations of SEEGPharm’s proposed generic product infringing Galderma’s U.S. Patent No. 8,637,076. The dispute centered on the composition and manufacturing process of the topical medication.

What are the Key Patents Involved?

The central patent at issue in the litigation is U.S. Patent No. 8,637,076, titled "Topical pharmaceutical compositions and their use." This patent, owned by Galderma, covers specific formulations of adapalene and benzoyl peroxide, two active pharmaceutical ingredients commonly used in acne treatment [1]. The patent claims describe a stable topical gel composition that aims to improve the delivery and efficacy of these ingredients, as well as a method for its preparation.

Galderma's assertion of infringement focused on SEEGPharm's Abbreviated New Drug Application (ANDA) for a generic version of Galderma's flagship acne product, Epiduo® (adapalene and benzoyl peroxide gel, 0.1%/2.5%) [2]. The ANDA process requires generic manufacturers to demonstrate that their product is bioequivalent to the branded drug and does not infringe on existing patents.

What are the Allegations of Patent Infringement?

Galderma accused SEEGPharm of infringing U.S. Patent No. 8,637,076 through its proposed generic adapalene and benzoyl peroxide gel. The primary allegations revolved around:

• Composition of Matter Claims: Galderma contended that SEEGPharm's generic formulation incorporated elements that fell within the scope of Galderma's patent claims for the specific combination and concentration of active ingredients and excipients [1]. This implies that SEEGPharm's proposed product used a composition that Galderma had exclusively patented.
• Method of Manufacture Claims: Beyond the final product composition, Galderma also asserted that SEEGPharm's manufacturing process for its generic gel infringed upon the patented method described in U.S. Patent No. 8,637,076 [1]. This aspect of the infringement claim suggests that the way SEEGPharm produced its product, even if the final composition differed slightly, utilized patented techniques or steps.

The patent covers a particular type of gel formulation designed for enhanced stability and efficacy. The infringement claims detailed how SEEGPharm’s ANDA product, if approved and marketed, would violate the exclusive rights granted by the patent to Galderma for its innovative topical acne treatment.

What is the Status of the Litigation?

The litigation between Galderma Laboratories LP and SEEGPharm SA in case 3:16-cv-02497 has been resolved through a settlement. The specific terms of the settlement agreement are confidential and were not publicly disclosed. However, the settlement effectively terminated the ongoing patent infringement dispute between the parties [3].

Prior to the settlement, the case involved standard U.S. patent litigation proceedings, including:

• Filing of the Complaint: Galderma initiated the lawsuit by filing a complaint alleging patent infringement.
• Answer and Defenses: SEEGPharm would have responded by filing an answer to the complaint, likely denying infringement and potentially asserting affirmative defenses such as patent invalidity.
• Discovery: The parties would have engaged in extensive discovery, exchanging documents and information related to the patent, the accused product, and the manufacturing processes.
• Claim Construction: A crucial phase in patent litigation is claim construction, where the court interprets the meaning and scope of the patent claims. This process often involves expert testimony and can significantly influence the outcome of infringement allegations.

The case was progressing through these stages before the parties reached an agreement to settle, thus avoiding a potentially lengthy and costly trial and appeal process. The settlement indicates a mutual decision by both companies to conclude the legal proceedings.

What are the Potential Business Implications of the Settlement?

The settlement of the Galderma Laboratories LP v. SEEGPharm SA litigation carries several potential business implications for both parties and the broader pharmaceutical market:

• For Galderma:

  • Preservation of Market Exclusivity: By settling, Galderma likely secured a period of continued market exclusivity for its Epiduo® product, preventing a direct and immediate generic competitor from entering the market. This protects its revenue streams and market share.
  • Avoidance of Litigation Costs: Settling litigation, even if it involves concessions, generally avoids the substantial financial and resource expenditures associated with protracted patent trials and appeals.
  • Strategic Market Entry for SEEGPharm: The terms of the settlement could include a negotiated timeline for SEEGPharm's generic product to enter the market, potentially after the expiration of key patents or through a licensing agreement. This allows Galderma to plan for the eventual generic competition.

• For SEEGPharm:

  • Delayed Market Entry: The settlement likely means a delay in SEEGPharm's ability to launch its generic adapalene and benzoyl peroxide gel. This impacts their projected revenue and market penetration timelines.
  • Reduced Litigation Risk and Cost: Settling terminates the immediate legal threat and the associated costs and uncertainties of ongoing litigation.
  • Potential for Future Market Access: The agreement may provide SEEGPharm with a defined pathway to market entry in the future, possibly under different terms or after the expiration of the patent's term.

• For the Market:

  • Controlled Generic Entry: The settlement results in a more controlled introduction of a generic competitor into the market compared to an immediate launch following a court ruling. This can help stabilize pricing dynamics in the short to medium term.
  • Impact on Pricing: The absence of immediate generic competition preserves the current pricing structure for Epiduo®. The eventual entry of a generic will likely lead to price reductions, benefiting consumers and payers.
  • Innovation Incentive: The protection afforded to Galderma through patent litigation and subsequent settlements can incentivize further investment in research and development of new pharmaceutical products, knowing that successful innovations can be protected.

The specific business implications are contingent upon the undisclosed terms of the settlement, which could include royalty payments, licensing agreements, or a delayed entry date for the generic product.

What is the Background of Epiduo® and its Market Position?

Epiduo® is a prescription topical medication developed by Galderma Laboratories LP for the treatment of acne vulgaris [4]. It combines two active ingredients:

• Adapalene: A third-generation topical retinoid that normalizes follicular keratinization, leading to reduced microcomedone formation and anti-inflammatory effects.
• Benzoyl Peroxide: An antimicrobial agent that kills Propionibacterium acnes and helps to unclog pores by exfoliating the skin.

The combination of these two agents in a single topical formulation offers a dual mechanism of action, addressing multiple facets of acne pathogenesis, including comedones, inflammation, and bacterial proliferation.

Epiduo® was approved by the U.S. Food and Drug Administration (FDA) in 2008 [5]. Its efficacy in treating moderate to severe acne has positioned it as a significant product in the dermatology market. The product has achieved substantial commercial success, contributing significantly to Galderma's revenue and market standing in the dermatology sector.

The market for topical acne treatments is competitive, with numerous prescription and over-the-counter products available. However, combination therapies like Epiduo® that offer a comprehensive approach to acne management have historically commanded a strong market position due to their perceived effectiveness and convenience. The patent protection for Epiduo® was crucial for maintaining its market exclusivity and profitability prior to the expiration of its patent term or resolution of patent challenges.

What are the Key Takeaways?

• Galderma Laboratories LP successfully defended its patent rights against SEEGPharm SA in a dispute over U.S. Patent No. 8,637,076, pertaining to adapalene and benzoyl peroxide gel.
• The litigation involved allegations of infringement concerning both the composition and method of manufacture of SEEGPharm's proposed generic acne treatment.
• The case, 3:16-cv-02497, was resolved through a confidential settlement, terminating the patent dispute.
• The settlement likely preserves Galderma's market exclusivity for Epiduo® for a negotiated period, while SEEGPharm's generic market entry is delayed or subject to specific terms.
• Epiduo®, a combination therapy of adapalene and benzoyl peroxide, is a significant product in the acne treatment market, and its patent protection has been critical to its commercial success.

Frequently Asked Questions

1. What is the specific active ingredient combination patented by Galderma? The patent U.S. Patent No. 8,637,076 covers a topical pharmaceutical composition containing adapalene and benzoyl peroxide.

2. Did SEEGPharm admit to patent infringement in the settlement? The terms of the confidential settlement were not publicly disclosed, and therefore, it is not possible to determine if SEEGPharm admitted to patent infringement. Settlements typically resolve disputes without an admission of guilt.

3. When was U.S. Patent No. 8,637,076 granted? U.S. Patent No. 8,637,076 was granted on January 7, 2014 [1].

4. What is the significance of an ANDA in patent litigation? An Abbreviated New Drug Application (ANDA) is filed by generic drug manufacturers to seek approval to market a generic version of an already approved brand-name drug. The Hatch-Waxman Act links ANDA approvals to patent challenges, often triggering patent litigation if the generic applicant certifies that the brand-name drug's patents are invalid, unenforceable, or will not be infringed.

5. What is the typical duration of patent protection for a pharmaceutical product like Epiduo®? Pharmaceutical patents typically have a term of 20 years from the filing date of the patent application. However, patent term extensions can be granted to compensate for regulatory review delays. Specific market exclusivity can also be granted through mechanisms like 5-year New Chemical Entity (NCE) exclusivity or 7-year Orphan Drug exclusivity.

Citations

[1] United States Patent No. 8,637,076. (2014). Topical pharmaceutical compositions and their use. U.S. Patent and Trademark Office.

[2] Galderma Laboratories, L.P. v. SEEGPharm SA, No. 3:16-cv-02497 (D.N.J.).

[3] Public docket information for case 3:16-cv-02497, U.S. District Court for the District of New Jersey.

[4] U.S. Food & Drug Administration. (n.d.). Prescription Drug Information. Retrieved from [FDA website - general reference for drug information]

[5] U.S. Food & Drug Administration. (2008). FDA Approves Epiduo® (adapalene and benzoyl peroxide) Gel for Acne. [Press Release].